Quick Facts: Diamicron (Gliclazide)

• Primary therapeutic use: Management of elevated blood sugar levels (hyperglycemia).
• Condition: Indicated for adults with Type 2 Diabetes Mellitus.
• Context of use: Generally considered when dietary measures, physical exercise, and weight reduction alone do not provide adequate control of blood glucose.

---

Diamicron (gliclazide) is indicated for the management of blood glucose levels in adults diagnosed with Type 2 Diabetes Mellitus. The medication is used in a regimen alongside a structured diet, weight management, and physical activity plan.

Its main use is to help achieve and maintain appropriate blood sugar control when lifestyle changes alone are insufficient. Maintaining blood glucose may contribute to reducing the potential for long-term health complications associated with diabetes.

The medication is designed to work by influencing the body's natural processes that manage glucose. It serves as a component of a comprehensive management plan for maintaining stable blood sugar levels.

Who Can and Cannot Use Diamicron (Gliclazide)

Official regulatory documents define strict eligibility criteria for the use of Gliclazide, the active ingredient in Diamicron. Use is primarily established for adults diagnosed with Type 2 Diabetes Mellitus.

Contraindications and Non-Eligibility

Diamicron is contraindicated and must not be used in patients with the following conditions:

• Type 1 Diabetes Mellitus, diabetic keto-acidosis, or diabetic pre-coma.
• Known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
• Severe hepatic (liver) impairment or severe renal (kidney) impairment.
• During pregnancy or breastfeeding.
• Concomitant treatment with miconazole (systemic or oromucosal gel).

Age and Special Populations

Population	Regulatory Status
Children & Adolescents (under 18)	Not Recommended: Safety and efficacy have not been established.
Older Adults	Eligible: Use requires careful monitoring due to increased sensitivity and risk of hypoglycemia.

Eligibility-related restrictions also apply to patients who are severely malnourished, have severe vascular disease, or possess G6PD deficiency, often requiring special caution or consideration of alternative treatment.

Interactions with other medicines and products

Diamicron (Gliclazide) has officially documented interaction patterns that influence its effectiveness and the stability of blood glucose control. These interactions are categorized by their effect and regulatory status.

Formal Contraindication

Co-administration with Miconazole (systemic route or oromucosal gel) is formally prohibited according to regulatory documents. This combination is documented to cause severe potentiation of the hypoglycaemic effect, carrying a risk of coma.

Potentiation and Increased Risk of Hypoglycaemia

Many substances can lead to a pharmacodynamic potentiation of the glucose-lowering effect. These include other antidiabetic agents (such as Insulin), Beta-blockers, ACE Inhibitors, and certain antifungal medicines like Fluconazole. Substances such as systemic Phenylbutazone are documented to increase Gliclazide's exposure by reducing its elimination or displacing its plasma protein binding.

Reduced Efficacy and Hyperglycaemia Risk

Substances that either reduce Gliclazide exposure or directly raise blood glucose can decrease treatment efficacy. St. John's Wort preparations are officially documented to decrease Gliclazide exposure. Other interacting substances, including Glucocorticoids and Danazol, are noted to cause an increase in blood glucose levels.

Substance and Population Constraints

Acute alcohol intoxication is officially documented to potentiate the hypoglycaemic action by inhibiting compensatory mechanisms, and its consumption must therefore be avoided. Population-specific cautions include an increased risk of blood glucose imbalance (dysglycaemia) when Fluoroquinolones are co-administered in elderly patients. Furthermore, use is formally contraindicated in severe hepatic or renal impairment due to the increased risk of severe and prolonged hypoglycaemia.

Specific K ATP Channel Blockade and Insulin Release

This core mechanism involves Gliclazide binding directly to the Sulfonylurea Receptor 1 ( SUR1) on the pancreatic beta-cell, which forces the ATP-sensitive K^+ ion channel to close. This targeted molecular interaction initiates a rapid cascade—membrane depolarization, calcium influx, and finally, the exocytosis of pre-formed insulin into the circulation . This physiological consequence leads to the system-wide effect of increased glucose uptake by peripheral tissues, reducing circulating glucose.

---

️ Extra-Pancreatic Antioxidant and Vascular Modulation

The unique chemical structure of Gliclazide provides distinct extra-pancreatic activities. It acts as an antioxidant, resulting in the modulation of oxidative stress and influencing the integrity of the beta-cells. Additionally, it modulates microvascular function by inhibiting factors related to platelet adhesion and aggregation, influencing pathways associated with microvascular and circulatory function.

---

Mechanistic Selectivity and Functional Constraint

The drug is mechanistically specific, showing a high preference for the pancreatic SUR1 receptor over the SUR2A receptors in cardiac tissue. This selectivity results in a focused mechanistic action primarily on the beta-cells. However, this entire mechanism is fundamentally constrained and requires the existence of residual, functional beta-cells capable of synthesizing and storing insulin for the drug to exert its insulin secretagogue activity.

How to Use Diamicron

Diamicron (gliclazide) Modified-Release (MR) is an oral medication with a standardized administration protocol to ensure consistent long-term use in adults with Type 2 Diabetes Mellitus.

Official Administration Protocol

Feature	Guideline
Route of Administration	The approved route is oral administration
Dosing Schedule (Adults)	Initial Dose: 30 mg daily. Maintenance Range: 30 mg to 120 mg daily. Maximum Daily Dose: 120 mg.
Timing & Meals	Must be taken once daily at breakfast time and with food to minimize the risk of hypoglycemia.
Special Handling	Tablets must be swallowed whole; they must not be crushed or chewed to preserve the modified-release action.

---

Usage Patterns and Adjustments

Dose Titration: The dose is not static; adjustment should be guided by the patient’s metabolic response, primarily blood glucose and HbA1 c levels. Dose increases should generally be made in 30 mg increments at intervals of at least one month. However, if no reduction in blood glucose is observed after two weeks of treatment, the dose may be increased sooner.

Missed Dose: If a daily dose is forgotten, the instruction is to skip the missed dose entirely. The dose taken on the subsequent day must not be increased to compensate for the skipped dose.

Specific Populations: For older adults (aged 65 and over) and patients with mild-to-moderate renal impairment, the same starting and maintenance dosing regimen applies, requiring careful monitoring.

These instructions define the structured, long-term oral administration of the Modified-Release formulation, outlining precisely when and how the medication is to be taken.

Research evidence / Overview of studies for Diamicron

---

Evidence for Glycemic Control in Type 2 Diabetes

The primary research for Gliclazide Modified-Release (MR) focuses on its use in adults with Type 2 Diabetes Mellitus. Research explored the medicine's role as a factor that was evaluated in research when lifestyle changes alone are not enough to measure blood glucose outcomes.

Studies conducted for Gliclazide include Randomized Controlled Trials (RCTs) and large Systematic Reviews that pool data from multiple trials. The core outcome measured in these trials was the change in Glycated Hemoglobin ( HbA1c), which is a physiological outcome researchers monitor related to blood sugar levels over time. Across many studies, findings describe patterns observed in the populations regarding the HbA1c values measured during the study period. While studies describe these shifts in glucose control, research provides context but not individual predictions about a person's expected response.

---

Long-Term Trials and Major Health Outcomes

Long-term research has been conducted to explore outcomes related to the potential long-term health consequences of diabetes. One of the most extensive research projects was a large, multi-year, multi-center RCT that specifically monitored the effects of a Gliclazide-based intensive glucose management approach over an average period of five years.

This research aimed to measure the incidence of major clinical outcomes, including composite endpoints for microvascular events (new or worsening disease affecting the eyes or kidneys) and macrovascular events (events like heart attack or stroke). Findings describe patterns observed in the studies related to microvascular health. Specifically, the intensive glucose control strategy using Gliclazide MR was associated with a statistically notable difference in the measurements of the composite microvascular endpoint, primarily related to a difference in kidney-related outcomes (nephropathy). Conversely, the same trial reported that the intensive strategy was not associated with a discernible difference in the primary composite endpoint for macrovascular events when observed against the standard control group.

---

The Current Research Landscape and Gaps

While the large trial provides significant data, long-term effects are not fully established outside of the specific study population. Limited Comparative Evidence exists for Gliclazide against all of the newer glucose-lowering drugs, such as SGLT2 inhibitors and GLP-1 receptor agonists, which were not available when the largest trials were conducted. Researchers caution that the results of the key clinical trials primarily reflect the specific conditions under which they were conducted. Evidence highlights what is known — and what is still uncertain.

Key Studies & References Gliclazide: Public Assessment Report (Gliclazide retard Teva 60 mg) - Example of Regulatory Review

Common questions about Diamicron (FAQ)

Q: What is Diamicron (Gliclazide) used for?

A: Diamicron (Gliclazide) is a medication primarily used to manage type 2 diabetes mellitus in adults. It belongs to a class of drugs called sulfonylureas.

It works by helping the body produce and release more insulin from the pancreas. Insulin is a hormone essential for moving sugar (glucose) from the blood into the cells, where it's used for energy.

It is generally prescribed when diet, exercise, and weight reduction alone are not sufficient to control blood sugar levels.

---

Q: How should I take Diamicron?

A: Diamicron is an oral tablet taken by mouth.

• It is usually taken once or twice daily, depending on the formulation (standard or modified release) and your physician's instructions.
• It is generally recommended to take the medication with breakfast or the first main meal of the day to reduce the risk of low blood sugar (hypoglycemia).

Always follow the specific instructions provided by your healthcare provider regarding dosage, timing, and whether it should be taken with food. Do not stop taking the medication or change the dose without consulting your doctor.

---

Q: What are the potential side effects of Diamicron?

A: The most common and serious side effect of Diamicron, like other sulfonylureas, is hypoglycemia (low blood sugar).

Signs of hypoglycemia may include:

• Shakiness or trembling
• Sweating
• Confusion or irritability
• Rapid heartbeat
• Dizziness or lightheadedness
• Hunger

Other common side effects may include:

• Stomach upset (nausea, vomiting, diarrhea, or constipation)
• Headache
• Skin rash or itching
• Weight gain

If you experience signs of severe hypoglycemia, you should consume a source of fast-acting sugar (like glucose tablets, honey, or fruit juice) and seek immediate medical attention. Report all side effects to your healthcare provider.

---

Q: Does Diamicron cause weight gain?

A: Yes, weight gain is a recognized potential side effect associated with Diamicron (Gliclazide) and other medications in the sulfonylurea class.

This is thought to be due to the drug's effect on insulin release. Insulin helps the body store excess glucose, which can lead to fat storage and increased body weight.

Maintaining a healthy diet and regular physical activity, as advised by your healthcare provider, remains essential for managing both blood sugar levels and body weight while on this medication.

How to Store and Dispose of Diamicron (Gliclazide MR)

Official regulatory guidelines for Diamicron tablets focus on maintaining product stability and ensuring safe disposal.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below 30 C.
Protection	Keep in a cool, dry place, shielded from moisture and direct heat.
Packaging	Keep the tablets in their original sealed blister pack until the time of use.
Safety	Store the medication in a location that is out of the reach of children.

Disposal Instructions

To comply with environmental regulations, unused or expired Diamicron tablets must not be disposed of in household trash or flushed down a toilet. The official requirement is to return the unwanted medicine to a pharmacy or a designated pharmaceutical waste collection point for proper disposal.